Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561425 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
A Phase 1 study of Lymphomas Non-Hodgkin's B-Cell and Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by Galapagos.
- Active
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT06561425 is a Phase 1 study of Lymphomas Non-Hodgkin's B-Cell and Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Galapagos. The registered enrollment target is 130 participants. The trial reports 10 study locations across 2 states.
The verdict
NCT06561425, a Phase 1 study of Lymphomas Non-Hodgkin's B-Cell and Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Galapagos.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the second phase, participants will receive the selected dose(s) based on the results in the first phase.
Conditions Studied
Interventions
- GENETIC GLPG5101
Study Locations (10)
Other
- Antwerp University Hospital - Edegem
- UZ Leuven - Leuven
- CHU De Liège - Liège
- Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Academisch Medisch Centrum - Amsterdam
- Leiden University Medical Center - Leiden
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) - Rotterdam
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06561425
The ClinicalTrials.gov registry entry for NCT06561425 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galapagos, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphomas Non-Hodgkin's B-Cell appearing as the primary indexed condition, and to 1 intervention - of which GLPG5101 is the first listed.
NCT06561425 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06561425 about?
NCT06561425 is a clinical study titled "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma". This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the s...
What is the current status of trial NCT06561425?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2022-03-09. Estimated completion is 2029-07-01.
What conditions does trial NCT06561425 study?
This clinical trial studies the following conditions: Lymphomas Non-Hodgkin's B-Cell, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06561425?
The interventions under investigation include: GLPG5101 (GENETIC).
Who is sponsoring clinical trial NCT06561425?
This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561425 being conducted?
This trial has 10 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphomas Non-Hodgkin's B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Lymphomas Non-Hodgkin's B-Cell
All registered trials for this condition
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.